Prospective, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of Two Different Doses of NT 201 in Botulinum Toxin Treatment-naive Subjects With Blepharospasm

Trial Profile

Prospective, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of Two Different Doses of NT 201 in Botulinum Toxin Treatment-naive Subjects With Blepharospasm

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Blepharospasm
  • Focus Registrational; Therapeutic Use
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 22 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 24 May 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.
    • 30 Mar 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top